Cargando…
Pimecrolimus interferes the therapeutic efficacy of human mesenchymal stem cells in atopic dermatitis by regulating NFAT-COX2 signaling
BACKGROUND: Human mesenchymal stem cells (hMSCs) therapy has recently been considered a promising treatment for atopic dermatitis (AD) due to their immunomodulation and tissue regeneration ability. In our previous studies, we demonstrated that hMSCs alleviate allergic inflammation in murine AD model...
Autores principales: | Shin, Nari, Jung, Namhee, Lee, Seung-Eun, Kong, Dasom, Kim, Nam Gyo, Kook, Myung Geun, Park, Hwanhee, Choi, Soon Won, Lee, Seunghee, Kang, Kyung-Sun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8399851/ https://www.ncbi.nlm.nih.gov/pubmed/34454603 http://dx.doi.org/10.1186/s13287-021-02547-8 |
Ejemplares similares
-
Treatment of atopic dermatitis with pimecrolimus – impact on quality of life
por: Lee, Hae-Hyuk, et al.
Publicado: (2007) -
Pimecrolimus for the Treatment of Atopic Dermatitis in Infants: An Asian Perspective
por: Chu, Chia-Yu, et al.
Publicado: (2023) -
Formulary Review of Therapeutic Alternatives for Atopic Dermatitis: Focus on Pimecrolimus
por: Weinberg, Jeffery M.
Publicado: (2005) -
Efficacy and tolerance of tacrolimus and pimecrolimus for atopic dermatitis: a meta-analysis
por: Yin, Zhiqiang, et al.
Publicado: (2011) -
Pimecrolimus in atopic dermatitis: Consensus on safety and the need to allow use in infants
por: Luger, Thomas, et al.
Publicado: (2015)